ASCO GU 2026: Updates in metastatic prostate cancer
CML treatment options are diverse, and informed choices are crucial for patients. Life expectancy for newly diagnosed patients is improving, especially in India, where patients are generally younger and more symptomatic. The ELTS score may better stratify risk for Indian patients compared to the SoCal scoring system. Key goals include achieving treatment-free remission and minimizing toxicities, with specific recommendations for using Imatinib and considering patient comorbidities.
ASCO GU 2026: Updates in metastatic prostate cancer
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing Wisely in endometrial & cervix cancers: Medical therapy
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Addressing the rise of multiple myeloma in Rwanda
ASCO 2024: Lung cancer highlights